CG Oncology, Inc. (CGON)

Nasdaq · Healthcare · Biotechnology
$79.47-2.97%As of 2026-11-22 · USD
Last session low $79.23Last session high $83.12
52-week low $37.0152-week high $93.95
Market cap
$7.10B
Sector
Healthcare

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)62.0In the neutral range (30 to 70)
MACD (12, 26, 9)4.02Above its signal line (2.66); histogram 1.36
Bollinger %B (20, 2)79%Inside the bands (56.41 to 85.76)
SMA 2071.09Price is 11.8% above
SMA 5068.87Price is 15.4% above
SMA 20067.39Price is 17.9% above
ATR (20)6.34% of priceAverage true range per day
52-week position75%In the upper part of the 37.01 to 93.95 range

About CG Oncology, Inc.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.

Insider filings, 90 daysNo purchases and 2 sales (about $135K).
Latest fiscal yearEnded 2025-12-31: revenue of $4.04M and an operating margin of -4722.1%.

More in Biotechnology